SINGAPORE –
Media OutReach Newswire – 16 December 2025 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has expanded its partnership with H. Lundbeck A/S (“Lundbeck”), a biopharmaceutical company focusing exclusively on brain health.
Under this new agreement, Zuellig Pharma will take on the role of agency partner to commercialize Lundbeck’s portfolio of products – including leading brands such as Lexapro®, Brintellix® and Cipralex® – across Indonesia, Malaysia, the Philippines and Singapore. This builds on its existing distribution agreement with Lundbeck, under which Zuellig Pharma has been responsible for distributing the company’s products in the four markets. In addition, Zuellig Pharma will also partner with Lundbeck in Taiwan.
As part of the expanded partnership, Zuellig Pharma will provide end-to-end commercialization and healthcare services, including marketing and commercial execution, market access, distribution and supply chain management, medical information services, regulatory and quality support, as well as pharmacovigilance for Lundbeck’s portfolio.
This collaboration is grounded in Zuellig Pharma’s ability to deliver consistent, high-quality access to medicines across the region. The company’s regional network and local market expertise will provide a strong foundation for Lundbeck to continue serving patients that rely on its products.
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
Hashtag: #ZuelligPharma #Lundbeck #Healthcare #BrainHealth #Pharmaceutical #HealthcareSolutions #Commercialization
The issuer is solely responsible for the content of this announcement.
